Tien Liang BioTech Co., Ltd. (TPEX:4127)
Taiwan
· Delayed Price · Currency is TWD 36.60
-0.05 (-0.14%)
Jun 20, 2025, 1:30 PM CST
Tien Liang BioTech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 383.94 | 385.21 | 459.99 | 528.52 | 571.32 | 431.08 | Upgrade
|
| Revenue Growth (YoY) | -15.20% | -16.26% | -12.97% | -7.49% | 32.53% | -1.10% | Upgrade
|
| Cost of Revenue | 154.58 | 155.29 | 173.85 | 191.98 | 233.04 | 179.13 | Upgrade
|
| Gross Profit | 229.35 | 229.91 | 286.15 | 336.55 | 338.28 | 251.96 | Upgrade
|
| Selling, General & Admin | 224.87 | 226.84 | 266 | 276.86 | 294.14 | 301.4 | Upgrade
|
| Research & Development | 2.85 | 2.48 | 1.28 | 1.4 | 1.2 | 1.24 | Upgrade
|
| Operating Expenses | 227.73 | 229.32 | 267.27 | 278.26 | 295.33 | 302.64 | Upgrade
|
| Operating Income | 1.63 | 0.59 | 18.87 | 58.29 | 42.95 | -50.68 | Upgrade
|
| Interest Expense | -4.5 | -3.08 | -2.08 | -1.77 | -1.85 | -1.96 | Upgrade
|
| Interest & Investment Income | 9.81 | 4.83 | 0.6 | 0.14 | 0.03 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 11.13 | 6.16 | 0.1 | -0.45 | -0.06 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.07 | 2.35 | 0.35 | 3.09 | 7.71 | 3.8 | Upgrade
|
| EBT Excluding Unusual Items | 20.13 | 10.84 | 17.84 | 59.3 | 48.78 | -48.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.93 | 2.93 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.68 | -0.68 | 0.57 | 0.03 | - | 0.16 | Upgrade
|
| Pretax Income | 22.38 | 13.1 | 18.42 | 59.33 | 48.78 | -48.59 | Upgrade
|
| Income Tax Expense | 0.62 | 1.4 | 0.68 | -0.15 | 2.18 | 3.04 | Upgrade
|
| Earnings From Continuing Operations | 21.76 | 11.7 | 17.73 | 59.48 | 46.61 | -51.64 | Upgrade
|
| Net Income | 21.76 | 11.7 | 17.73 | 59.48 | 46.61 | -51.64 | Upgrade
|
| Net Income to Common | 21.76 | 11.7 | 17.73 | 59.48 | 46.61 | -51.64 | Upgrade
|
| Net Income Growth | 15.78% | -34.04% | -70.19% | 27.63% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 46 | 46 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 46 | 46 | 46 | 46 | 46 | Upgrade
|
| Shares Change (YoY) | -0.04% | -0.04% | 0.01% | 0.05% | - | - | Upgrade
|
| EPS (Basic) | 0.48 | 0.26 | 0.39 | 1.30 | 1.02 | -1.13 | Upgrade
|
| EPS (Diluted) | 0.48 | 0.26 | 0.39 | 1.30 | 1.02 | -1.13 | Upgrade
|
| EPS Growth | 15.78% | -34.04% | -70.19% | 27.63% | - | - | Upgrade
|
| Free Cash Flow | 39.29 | 44.3 | 64.71 | 20.87 | 44.61 | -11.91 | Upgrade
|
| Free Cash Flow Per Share | 0.86 | 0.97 | 1.41 | 0.46 | 0.97 | -0.26 | Upgrade
|
| Dividend Per Share | - | - | 0.500 | - | - | - | Upgrade
|
| Gross Margin | 59.74% | 59.69% | 62.21% | 63.68% | 59.21% | 58.45% | Upgrade
|
| Operating Margin | 0.42% | 0.15% | 4.10% | 11.03% | 7.52% | -11.76% | Upgrade
|
| Profit Margin | 5.67% | 3.04% | 3.85% | 11.25% | 8.16% | -11.98% | Upgrade
|
| Free Cash Flow Margin | 10.23% | 11.50% | 14.07% | 3.95% | 7.81% | -2.76% | Upgrade
|
| EBITDA | 10.27 | 9.25 | 28.82 | 68.28 | 54.15 | -37.05 | Upgrade
|
| EBITDA Margin | 2.68% | 2.40% | 6.26% | 12.92% | 9.48% | -8.59% | Upgrade
|
| D&A For EBITDA | 8.65 | 8.66 | 9.94 | 10 | 11.21 | 13.63 | Upgrade
|
| EBIT | 1.63 | 0.59 | 18.87 | 58.29 | 42.95 | -50.68 | Upgrade
|
| EBIT Margin | 0.42% | 0.15% | 4.10% | 11.03% | 7.52% | -11.76% | Upgrade
|
| Effective Tax Rate | 2.75% | 10.70% | 3.71% | - | 4.46% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.